The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2022 Aug 29

PMID 36033393

Authors

Ze-Tao Zhan

Lu Liu

Ming-Zhen Cheng

Yi Gao

Wei-Jie Zhou

Affiliations

Soon will be listed here.

Abstract

Diabetes and cancer are common diseases and are frequently diagnosed in the same individual. These patients need to take antidiabetic drugs while receiving antitumor drugs therapy. Recently, immunotherapy offers significant advances for cancer treatment. However, it is unclear whether antidiabetic drugs affect immunotherapy. Here, by employing syngeneic mouse colon cancer model and melanoma model, we studied the effects of 6 common antidiabetic drugs on anti-PD1 immune checkpoint inhibitor in tumor treatment, including acarbose, sitagliptin, metformin, glimepiride, pioglitazone, and insulin. We found that acarbose and sitagliptin enhanced the tumor inhibition of anti-PD1, and metformin had no effect on the tumor inhibition of anti-PD1, whereas glimepiride, pioglitazone, and insulin weakened the tumor inhibition of anti-PD1. Our study suggests that cancer patients receiving anti-PD1 antibody therapy need serious consideration when choosing antidiabetic drugs. In particular, acarbose significantly inhibited tumor growth and further enhanced the therapeutic effect of anti-PD1, which can be widely used in tumor therapy. Based on this study, further clinical trials are expected.

Citing Articles

Combining Sulfonylureas with Anticancer Drugs: Evidence of Synergistic Efficacy with Doxorubicin In Vitro and In Vivo.

Tomczyk M, Matczak K, Denel-Bobrowska M, Dzido G, Kubicka A, Gendosz de Carrillo D Int J Mol Sci. 2025; 26(4).

PMID: 40003896 PMC: 11855866. DOI: 10.3390/ijms26041429.

Anti-Diabetic Therapies and Cancer: From Bench to Bedside.

Kounatidis D, Vallianou N, Karampela I, Rebelos E, Kouveletsou M, Dalopoulos V Biomolecules. 2024; 14(11).

PMID: 39595655 PMC: 11591849. DOI: 10.3390/biom14111479.

Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.

Dhas Y, Biswas N, M R D, Jones L, Ashili S Mol Biomed. 2024; 5(1):40.

PMID: 39333445 PMC: 11436690. DOI: 10.1186/s43556-024-00204-z.

Associations between Diabetes Mellitus and Selected Cancers.

Pliszka M, Szablewski L Int J Mol Sci. 2024; 25(13).

PMID: 39000583 PMC: 11242587. DOI: 10.3390/ijms25137476.

Diabetes Mellitus and Thyroid Cancers: Risky Correlation, Underlying Mechanisms and Clinical Prevention.

Wu R, Zhang J, Zou G, Li S, Wang J, Li X Diabetes Metab Syndr Obes. 2024; 17:809-823.

PMID: 38380275 PMC: 10878320. DOI: 10.2147/DMSO.S450321.

References

Noto H, Goto A, Tsujimoto T, Noda M . Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012; 7(3):e33411. PMC: 3308971. DOI: 10.1371/journal.pone.0033411. View

Pernicova I, Korbonits M . Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014; 10(3):143-56. DOI: 10.1038/nrendo.2013.256. View

Evans J, Donnelly L, Emslie-Smith A, Alessi D, Morris A . Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330(7503):1304-5. PMC: 558205. DOI: 10.1136/bmj.38415.708634.F7. View

Libby G, Donnelly L, Donnan P, Alessi D, Morris A, Evans J . New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32(9):1620-5. PMC: 2732153. DOI: 10.2337/dc08-2175. View

Cha J, Yang W, Xia W, Wei Y, Chan L, Lim S . Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018; 71(4):606-620.e7. PMC: 6786495. DOI: 10.1016/j.molcel.2018.07.030. View

Wang Q, Lu P, Wang T, Zheng Q, Li Y, Leng S . Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma-associated antigen-A3 expression through Yes-associated protein inactivation. Cancer Med. 2020; 9(11):3816-3828. PMC: 7286447. DOI: 10.1002/cam4.3024. View

Lebovitz H . Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep. 2019; 19(12):151. PMC: 6881429. DOI: 10.1007/s11892-019-1270-y. View

Yorifuji N, Inoue T, Iguchi M, Fujiwara K, Kakimoto K, Nouda S . The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice. Oncol Rep. 2015; 35(2):676-82. DOI: 10.3892/or.2015.4429. View

Mamtani R, Haynes K, Bilker W, Vaughn D, Strom B, Glanz K . Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 2012; 104(18):1411-21. PMC: 3529598. DOI: 10.1093/jnci/djs328. View

10.

Kosowska A, Garczorz W, Klych-Ratuszny A, Aghdam M, Kimsa-Furdzik M, Simka-Lampa K . Sitagliptin Modulates the Response of Ovarian Cancer Cells to Chemotherapeutic Agents. Int J Mol Sci. 2020; 21(23). PMC: 7731375. DOI: 10.3390/ijms21238976. View

11.

Chung Y, Han D, Park K, Eun C, Yoo K, Park C . Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum. 2008; 51(5):593-7. DOI: 10.1007/s10350-007-9184-1. View

12.

Thakkar B, Aronis K, Vamvini M, Shields K, Mantzoros C . Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013; 62(7):922-34. DOI: 10.1016/j.metabol.2013.01.014. View

13.

Tseng C . Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest. 2015; 46(1):70-9. DOI: 10.1111/eci.12570. View

14.

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

15.

Koro C, Barrett S, Qizilbash N . Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf. 2006; 16(5):485-92. DOI: 10.1002/pds.1352. View

16.

Coughlin S, Calle E, Teras L, Petrelli J, Thun M . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159(12):1160-7. DOI: 10.1093/aje/kwh161. View

17.

Jabbour S . Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?. Int J Clin Pract. 2008; 62(6):845-7. DOI: 10.1111/j.1742-1241.2008.01757.x. View

18.

Wu Y, Liu H, Shi X, Song Y . Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis. PLoS One. 2014; 9(6):e99577. PMC: 4055722. DOI: 10.1371/journal.pone.0099577. View

19.

Tseng C, Lee K, Tseng F . An updated review on cancer risk associated with incretin mimetics and enhancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015; 33(1):67-124. DOI: 10.1080/10590501.2015.1003496. View

20.

Chang C, Lin J, Wu L, Lai M, Chuang L . Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97(7):E1170-5. DOI: 10.1210/jc.2012-1162. View